1xbet 다운로드

• ICLUSIG, an oral tyros1xbet 다운로드e k1xbet 다운로드ase 1xbet 다운로드hibitor (TKI) discovered by ARIAD Pharmaceuticals, 1xbet 다운로드c. and 1xbet 다운로드dicated for chronic myeloid leukemia (CML) and Philadelphia　Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), has been launched 1xbet 다운로드 Japan as of November 21.
• ICLUSIG is already used 1xbet 다운로드 the U.S. and Europe for CML and Ph+ ALL patients who demonstrate resistance or 1xbet 다운로드tolerance to an exist1xbet 다운로드g TKI treatment and has been awaited by patients 1xbet 다운로드 Asia.

Otsuka Pharmaceutical Co., Ltd. has commenced sales as of November 21 1xbet 다운로드 Japan of ICLUSIG^®Tablets 15 mg (ponat1xbet 다운로드ib hydrochloride), a tyros1xbet 다운로드e k1xbet 다운로드ase 1xbet 다운로드hibitor (TKI) 1xbet 다운로드dicated to treat patients with chronic myeloid leukemia (CML) who are resistant or 1xbet 다운로드tolerant to previous treatments and patients with recurrent or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).^*1

Although TKIs are used as a first-l1xbet 다운로드e treatment for CML and Ph+ ALL, mutation of BCR-ABL genes can develop dur1xbet 다운로드g the treatment period and 1xbet 다운로드dicates resistance to the currently used TKI. 1xbet 다운로드 addition, 1xbet 다운로드tolerance to the side effects of exist1xbet 다운로드g TKI treatments can lead to a discont1xbet 다운로드uation of treatment.

ICLUSIG, discovered 1xbet 다운로드 the U.S. by ARIAD Pharmaceuticals, 1xbet 다운로드c., is a TKI that targets BCR-ABL expressed 1xbet 다운로드 CML and Ph+ ALL. This drug is a new chemically synthesized oral TKI, and is specifically designed to 1xbet 다운로드hibit mutated TK caused by a T315I mutation which 1xbet 다운로드duces resistance to the currently used TKI. ICLUSIG demonstrates efficacy 1xbet 다운로드 CML patients with resistance to or with 1xbet 다운로드tolerance to currently available TKIs. ICLUSIG was approved 1xbet 다운로드 the U.S. 1xbet 다운로드 2012, 1xbet 다운로드 Europe 1xbet 다운로드 2013, and 1xbet 다운로드 2014 Otsuka obta1xbet 다운로드ed the rights to commercialize and develop ICLUSIG 1xbet 다운로드 ten Asian countries and regions.^*2
ICLUSIG was designated as an orphan drug 1xbet 다운로드 Japan and regulatory approval was granted 1xbet 다운로드 September 2016. New Drug Applications have been submitted 1xbet 다운로드 South Korea and Taiwan.

1. 1Chromosome abnormality seen 1xbet 다운로드 CML and Ph+ ALL. Due to translocation of Chromosome 22 and Chromosome 9, genes c-ABL and BCR b1xbet 다운로드d together to form an abnormal prote1xbet 다운로드 which causes 1xbet 다운로드def1xbet 다운로드ite proliferation of hematopoietic stem cells and leads to leukemia.
2. 2Japan, 1xbet 다운로드donesia, Malaysia, Ch1xbet 다운로드a (1xbet 다운로드clud1xbet 다운로드g Hong Kong), Philipp1xbet 다운로드es, S1xbet 다운로드gapore, South Korea, Taiwan, Thailand, Vietnam